English

RLS Global AB (publ) Interim Report, Q3, 2021

Report this content

JULY 1st – SEPTEMBER 3Oth

  • Net sales amounted to TSEK 132 (TSEK 793)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -6,2 (MSEK -5,6)
  • Earning per share before dilution at SEK -0,09 (SEK-0,08)
  • Cash flow from operating activities amounted to MSEK 8,6 (MSEK-4,2)
  • Liquid assets at the end of the period MSEK 16,4 (MSEK 25,9)
  • Equity ratio was 86% (90%)

 

JAN 1st – SEPTEMBER 3Oth

  • Net sales amounted to TSEK 472 (TSEK 1 905)
  • Earnings before interest and taxes (EBIT) amounted to MSEK -4,0 (MSEK -15,0)
  • Earning per share before dilution at SEK -0,06 (SEK-0,23)
  • Cash flow from operating activities amounted to MSEK -3,4 (MSEK-15,2)
  • Liquid assets at the end of the period MSEK 16,4 (MSEK 25,9)
  • Equity ratio was 86% (90%)

 

SUMMARY OF EVENTS DURING THIRD QUARTER

  • Activities in order to receive reimbursement in the European countries are in progress.
  • The integration process with ConvaTec is in progress according to plan.
  • RLS has reactivated R&D activities with special focus on burns and pressure ulcers.
  • To meet future demand, RLS has initiated a project with the aim to automatize the production and improve the COGS.


COVID-19

  • RLS experiences an opening within the health care sector. However, there are still restrictions due to the effect of the pandemic.


 

 

Trading place and Certified AdvisEr
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012–2017, the company was listed on Aktietorget.

 

The Interim Report Q3, 2021, is enclosed and is also available here.

 

Publication
This information was submitted for publication through the agency of the below contact person, at 09.00 CET on Nov 12th 2021.

CONTACT INFORMATION

Karin Fischer, CEO
E-mail: karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail: eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop products for some of our most common illnesses in wound and oral care. RLS Global has a portfolio of strong brands, including ChloraSolv® and Carisolv®. The company is listed on Nasdaq First North with Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

Tags:

Life Science RLS medtech Wound Care wound healing RLS Global

Subscribe

Documents & Links